Treatments

Current Ivermectin Schedule Does Not Cure Strongyloidiasis

Current Ivermectin Schedule Does Not Cure Strongyloidiasis

By

Further studies are required to evaluate the effectiveness of the ivermectin schedule for treatment of strongyloidiasis, and quantitative methods of high sensitivity and accuracy are needed to monitor treatment success or to predict reactivation.

FDA Grants Priority Review for Smallpox Treatment

FDA Grants Priority Review for Smallpox Treatment

By

The FDA has accepted and granted priority review for TPOXX, an antiviral therapy for smallpox.

Oral Fexinidazole Safe, Effective for Late-Stage Trypanosomiasis

Oral Fexinidazole Safe, Effective for Late-Stage Trypanosomiasis

By

As first-line treatment for human African trypanosomiasis requires administration in a hospital by trained personal, a short-course oral option presents significant advantages for managing patients with this tropical disease.

Mogamulizumab is safe and possibly effective in HTLV-1-associated myelopathy

In this combined phase 1-2a study, mogamulizumab used for treatment of human T-lymphotropic virus type 1 associated myelopathy was safe and associated with improvement in biomarkers of disease, as well as improvements in spasticity and motor disability.

Antibiotic Prescribing Habits for UTI in Pregnant Women

Antibiotic Prescribing Habits for UTI in Pregnant Women

By

For pregnant women in their first trimester, a 2011 Committee Opinion from the ACOG recommended that sulfonamides and nitrofurantoin may be prescribed only if other antimicrobial therapies are deemed clinically inappropriate.

Lingering Symptoms of Post-Treatment Lyme Disease Explored

Lingering Symptoms of Post-Treatment Lyme Disease Explored

By

New research may explain why many patients report lingering symptoms after receiving antibiotic therapy for the treatment of Lyme disease.

Antibiotics Frequently Prescribed for Suspected UTI in Nursing Home Residents

Antibiotics Frequently Prescribed for Suspected UTI in Nursing Home Residents

By

Five factors were found to be significantly associated with UTI antibiotic use in order of decreasing association: presence of urinary catheter, urinary frequency, fever, new-onset hypotension, and confusion.

Assessment of Prolonged vs Short-Term Antipseudomonal β-lactam Infusion for Sepsis

Assessment of Prolonged vs Short-Term Antipseudomonal β-lactam Infusion for Sepsis

By

Researchers conducted a systematic review and meta-analysis to assess the effectiveness and safety of short-term vs prolonged infusion of antipseudomonal β-lactams in patients with sepsis.

Hepatitis C Drug Effective Against Zika Virus in Preclinical Trial

Hepatitis C Drug Effective Against Zika Virus in Preclinical Trial

By

The hepatitis C treatment, sofosbuvir was found to be effective against Zika virus in a preclinical trial.

FDA: Vancomycin Liquid Oral Treatment Approved for <i>C diff</i>-Associated Diarrhea

FDA: Vancomycin Liquid Oral Treatment Approved for C diff-Associated Diarrhea

By

Vancomycin is the first liquid oral treatment for C diff-associated diarrhea.

CDC Seasonal Influenza A(H3N2) Activity and Treatment Advisory

CDC Seasonal Influenza A(H3N2) Activity and Treatment Advisory

By

Recent significantly increased influenza activity prompts CDC advisory for antiviral treatment.

Ceftazidime-Avibactam Efficacious in Nosocomial Pneumonia

Ceftazidime-Avibactam Efficacious in Nosocomial Pneumonia

By

Results support a role for ceftazidime-avibactam as a potential alternative to carbapenems in patients with nosocomial pneumonia (including ventilator-associated pneumonia) caused by Gram-negative pathogens.

Shorter duration of glecaprevir-pibrentasvir effective against hepatitis C virus: The ENDURANCE trials

Both 8 and 12-week regimens of glecaprevir-pibrentasvir were highly efficacious in producing sustained virologic response in patients infected with hepatitis C virus genotypes 1 and 3, and the 8-week treatment duration was noninferior to 12-week duration.

Extended-Pulsed Fidaxomicin Superior to Vancomycin for Sustained CDI Cure in Elderly

Extended-Pulsed Fidaxomicin Superior to Vancomycin for Sustained CDI Cure in Elderly

By

The EXTEND study addresses sustained cure as a primary measure of treatment success in a high-risk patient population, with recurrence monitored up to day 90.

Shorter pediatric tuberculosis treatment linked to higher completion rates

Children with tuberculosis who received 3 months of directly observed preventative therapy were >25 times more likely to complete their treatment regimen than those who received 9 months of self-administered therapy.

Iclaprim Comparable With Vancomycin for Gram-Positive Acute Bacterial Skin Infections

Iclaprim Comparable With Vancomycin for Gram-Positive Acute Bacterial Skin Infections

By

Iclaprim was noninferior to vancomycin with respect to the early clinical response at an early time point in the treatment of ABSSSI caused or suspected to be caused by gram-positive organisms.

Reason for Hope: Promising Gram-Negative Infection Treatments in the Pipeline

Reason for Hope: Promising Gram-Negative Infection Treatments in the Pipeline

By

Dr McKinnell provides a summary of drugs in development for infections caused by Gram-negative bacteria, including carbapenem-resistant Pseudomonas aeruginosa and carbapenem-resistant Enterobacteriaceae.

How Often Do Patients Select Antibiotics Over Surgery for Acute Appendicitis?

How Often Do Patients Select Antibiotics Over Surgery for Acute Appendicitis?

Although most patients would choose surgical intervention for treatment of acute uncomplicated appendicitis, some would opt for antibiotics alone.

Safety of Clofazimine in Treating Children With <i>Mycobacterium abscessus</i> Infections

Safety of Clofazimine in Treating Children With Mycobacterium abscessus Infections

By

Clofazimine was safe and well-tolerated as part of a multidrug regimen for the treatment of children with Mycobacterium abscessus odontogenic infections.

Provider-Pharmacy Collaboration Reduces DAA Initiation Delays in HCV

Provider-Pharmacy Collaboration Reduces DAA Initiation Delays in HCV

Reduced DAA delays and denials for patients with HCV reduced with provider-pharmacy collaboration.

Priority Review Granted for Treatment of Complicated UTI, Bloodstream Infections

Priority Review Granted for Treatment of Complicated UTI, Bloodstream Infections

By

The FDA accepted a new drug application for plazomicin for complicated urinary tract infections.

Reducing Treatment of HPV+ Oropharyngeal Cancer May Compromise Safety

Reducing Treatment of HPV+ Oropharyngeal Cancer May Compromise Safety

Deintensification of treatment from chemoradiotherapy to one modality may compromise safety in patients with human papillomavirus (HPV)+ stage 1 or 2 oropharyngeal cancer.

Alternative Therapeutics for Mild Infections May Help to Retain Antibiotic Efficacy

Alternative Therapeutics for Mild Infections May Help to Retain Antibiotic Efficacy

By

Developing alternative, non-antibiotic treatments for certain "self-limiting infections" may help preserve the effectiveness of antibiotics.

New Immunotherapy Approach Shows Promise in Fight Against Antibiotic Resistance

New Immunotherapy Approach Shows Promise in Fight Against Antibiotic Resistance

By

A new immunotherapy approach has shown promise in it's first-in-human trial for antibiotic-resistant bacteria.

Prophylactic letermovir significantly reduces cytomegalovirus infection after transplantation

Letermovir prophylaxis significantly decreased the incidence of cytomegalovirus infection through 24 weeks following hematopoietic stem cell transplantation. Letermovir was associated with a significantly lower all-cause mortality compared to placebo and did not demonstrate any serious toxicities.

Diclofenac Inferior to Norfloxacin for UTI, May Increase Pyelonephritis Risk

Diclofenac Inferior to Norfloxacin for UTI, May Increase Pyelonephritis Risk

By

The benefit of antibiotic treatment needs to be weighed against the potential for adverse effects, at both the individual level (adverse drug reactions) and the population level (as a driver of antibiotic resistance).

High Rates of SVR With Interferon-Free DAA for HCV GT1, Advanced Fibrosis

High Rates of SVR With Interferon-Free DAA for HCV GT1, Advanced Fibrosis

By

Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin demonstrated high rates of adherence and SVR in different HCV patient subgroups, including patients with advanced fibrosis combined with chronic comorbidities.

First Oral Smallpox Treatment Submitted to FDA for NDA

First Oral Smallpox Treatment Submitted to FDA for NDA

By

A new drug application was submitted to the FDA for oral formula to treat smallpox.

MicroRNAs in Infectious Disease: Emerging Clinical Applications

MicroRNAs in Infectious Disease: Emerging Clinical Applications

By

MicroRNAs are currently under investigation for various clinical applications in infectious disease because of their role in host response to infection and effects on innate and adaptive immune pathways.

Fecal Microbial Transplantation by Oral Capsule Not Inferior to Colonoscopy Delivery

Fecal Microbial Transplantation by Oral Capsule Not Inferior to Colonoscopy Delivery

By

A study investigated whether fecal microbiota transplantation delivered via oral capsules was as effective as microbiota delivered via colonoscopy for treating recurrent Clostridium difficile infection.

Sign Up for Free e-newsletters